MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.480
+0.110
+3.26%
After Hours: 3.650 +0.17 +4.89% 17:56 03/05 EST
OPEN
3.550
PREV CLOSE
3.370
HIGH
3.680
LOW
3.250
VOLUME
793.46K
TURNOVER
--
52 WEEK HIGH
7.30
52 WEEK LOW
0.6153
MARKET CAP
77.47M
P/E (TTM)
-2.2113
1D
5D
1M
3M
1Y
5Y
PDS Biotech Announces Presentations in Upcoming Healthcare Investor Conferences
GlobeNewswire · 3d ago
Making A List Of Hot Penny Stocks? 4 Biotech Stocks To Watch This Week
Feb 24, 2021 (Penny Stocks via COMTEX) -- Are These Biotech Names On Your List Of Penny Stocks Right Now? Are you looking for penny stocks to buy right now?...
Penny Stocks · 02/24 21:10
Noble Financial Reiterates Their Buy Rating on PDS Biotechnology (PDSB)
In a report released yesterday, Ahu Demir from Noble Financial reiterated a Buy rating on PDS Biotechnology (PDSB), with a price target of $6.60. The
SmarterAnalyst · 02/24 07:22
Extensive Demand for T-Cell Adoptive Immunotherapy Rising with Growing Prevalence of Cancer
PALM BEACH,  Fla., /PRNewswire/ -- In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therap...
PR Newswire - PRF · 02/23 13:30
PDS Biotech and Farmacore join Blanver for COVID-19 vaccine development
PDS Biotechnology ([[PDSB]] +8.2%) and Farmacore Biotechnology announced a partnership with Blanver Farmoquímica e Farmacêutica S.A. to develop and commercialize a COVID-19 vaccine in Latin America.With the selection of a
Seekingalpha · 02/22 20:52
BRIEF-PDS Biotech And Farmacore Announce Blanver To Join Consortium To Commercialize Novel Versamune-Based T-Cell Inducing COVID-19 Vaccine
reuters.com · 02/22 15:50
PDS Biotechnology And Farmacore Biotechnology Announce Brazilian Pharmaceutical Company Blanver Has Joined Their Consortium To Develop And Commercialize A COVID-19 Vaccine In Latin America
FLORHAM PARK, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the
Benzinga · 02/22 13:33
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin AmericaFLORHAM PARK, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage im...
GlobeNewswire · 02/22 13:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PDSB. Analyze the recent business situations of PDS Biotechnology Corporation through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PDSB stock price target is 6.62 with a high estimate of 7.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 56
Institutional Holdings: 8.15M
% Owned: 36.60%
Shares Outstanding: 22.26M
TypeInstitutionsShares
Increased
8
228.64K
New
13
-356.82K
Decreased
2
21.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
Stephen Glover
President/Chief Executive Officer/Director
Frank Bedu-Addo
Chief Financial Officer
Seth Van Voorhees
Chief Scientific Officer
Gregory Conn
Other
Lauren Wood
Director
Otis Brawley
Director
Ilian Iliev
Independent Director
Kamil Ali-Jackson
Independent Director
DeLyle Bloomquist
Independent Director
Gregory Freitag
Independent Director
Richard Sykes
No Data
About PDSB
PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PDSB stock methods without spending real money on the virtual paper trading platform.